Should You Buy, Hold or Sell AXON Stock Post Q2 Earnings Release?

Backed by strength across end markets, management raised its full-year revenue outlook to 32-34% growth, up from 30-32% expected earlier, while maintaining an adjusted EBITDA margin target of approximately 25.5%. The updated view reflects continued momentum across the company’s connected devices and software offerings.

Let's take a closer look at the stock’s fundamentals and assess whether it's the right time to buy.

Factors Contributing to Axon Stock’s Performance

Axon is witnessing strong momentum in its Connected Devices segment. Segmental revenues surged 34.6% year over year in the second quarter of 2026, following an increase of 33% in the first quarter. Strong demand for its next-generation TASER 10 products, counter-drone equipment and virtual reality training services drove its results. Growing popularity for the company’s advanced body-worn camera, Axon Body 4, also augmented the segment’s growth. With upgraded features such as a bi-directional communications facility and a point-of-view camera module option, this body camera is generating significant demand.

In the second quarter, revenues from the company’s TASER product line increased 20.9% year over year, driven by TASER 10, while those from the Platform Solutions product line soared 122.6%, supported by counter-drone, virtual reality and fleet. Also, revenues from Personal Sensors increased 2.8%, led by Axon Body 4.

AXON is also benefiting from persistent strength in its Software & Services segment.  In the second quarter, the segment’s revenues increased 36.2% year over year. Higher adoption of its premium software offerings, including Axon Fusus, the AI Era Plan and Axon 911, and solid demand for premium add-on features are driving the segment’s growth.

Given the rising global demand for Counter-Unmanned Aircraft Systems (CUAS), Axon is also witnessing strong momentum in its Dedrone platform. After witnessing year-over-year growth of 300% in the first quarter, revenues from the Dedrone platform surpassed $100 million in the second quarter. The company also launched Dedrone C2, an upgraded version of the platform. This C2 version comes with enhanced sensor fusion technology, offering stronger detection capabilities.

AXON remains focused on strategic collaborations with other companies to expand its product offerings and customer base. In October 2025, Axon’s Dedrone business announced its partnership with TYTAN (a leading provider of interceptor systems for Group 3 drones) to boost detection, identification and mitigation capabilities of counter-drone equipment. The integration of TYTAN’s kinetic interceptor technology enhanced Dedrone’s CUAS mitigation capability, making it suitable to deploy against Group 3 threats.

AXON Shares Outperform Industry, S&P 500 & Peers

Shares of the company have gained 39.6% in the past six months compared with the industry and S&P 500 composite’s growth of 2.1% and 12.8%, respectively. It has also outpaced other industry players like Teledyne Technologies Incorporated TDY and Woodward, Inc. WWD, which have returned 3.9% and declined 4.4%, respectively, over the said time frame.

AXON Stock’s Six-Month Price Performance

Image Source: Zacks Investment Research

Axon’s Northward Earnings Estimates

The Zacks Consensus Estimate for AXON’s 2026 earnings per share has been stable at $7.83 in the past 60 days; the same for 2027 has remained unchanged at $10.64.

Image Source: Zacks Investment Research

Near-Term Concerns Prevail

The escalating costs and expenses are a concern for Axon’s bottom line. In the first six months of the year, its cost of sales increased 36.9% year over year to $688 million. Selling, general and administrative expenses were $550.1 million, while research and development expenses totaled $397.6 million in the same period, reflecting increases of 18.1% and 26.8%, respectively.

The adjusted gross margin decreased to 62.3% from 63.4% in the year-ago comparable period. A higher mix of professional services revenues and the scaling of newer products more than offset the benefits from global tariff refunds.

Axon has been facing the pressure of high debt levels. Exiting second-quarter 2026, the company’s long-term notes payable (net) were $1.73 billion. Considering its high debt level, its cash and cash equivalents of $597.7 million do not look impressive.

Stretched Valuation Remains an Overhang

AXON’s lofty valuation remains another concern. The stock is trading at a forward 12-month price-to-earnings (P/E) ratio of 62.71X, significantly higher than the industry average of 41.75X. This elevated valuation could make the stock vulnerable to further pullbacks if market sentiment sours. Also, the stock is overvalued compared with its peers, Teledyne Technologies and Woodward, which are trading at 26.45X and 35.47X, respectively.

Image Source: Zacks Investment Research

Our Final Take

Persistent strength across the Connected Devices and Software & Services segments, along with its investments in AI products, drones and robotics, positions AXON favorably for impressive growth in the long run. However, near-term challenges, such as escalating operating expenses, premium valuation and high debt, are limiting this Zacks Rank #3 (Hold) company’s near-term prospects.

While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains and provide a better entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research